Multiplexed In Vivo Screening Using Barcoded Aptamer Technology to Identify Oligonucleotide-Based Targeting Reagents
- 1 June 2024
- journal article
- research article
- Published by SAGE Publications in Nucleic Acid Therapeutics
- Vol. 34 (3) , 109-124
Abstract
Recent FDA approvals of mRNA vaccines, short-interfering RNAs, and antisense oligonucleotides highlight the success of oligonucleotides as therapeutics. Aptamers are excellent affinity reagents that can selectively label protein biomarkers, but their clinical application has lagged. When formulating a given aptamer for in vivo use, molecular design details can determine biostability and biodistribution; therefore, extensive postselection manipulation is often required for each new design to identify clinically useful reagents harboring improved pharmacokinetic properties. Few methods are available to comprehensively screen such aptamers, especially in vivo , constituting a significant bottleneck in the field. In this study, we introduce barcoded aptamer technology (BApT) for multiplexed screening of predefined aptamer formulations in vitro and in vivo . We demonstrate this technology by simultaneously investigating 20 aptamer formulations, each harboring different molecular designs, for targeting Non-Small Cell Lung Cancer cells and tumors. Screening in vitro identified a 45 kDa bispecific formulation as the best cancer cell targeting reagent, whereas screening in vivo identified a 30 kDa monomeric formulation as the best tumor-specific targeting reagent. The multiplexed analysis pipeline also identified biodistribution phenotypes shared among formulations with similar molecular architectures. The BApT approach we describe here has the potential for broad application to fields where oligonucleotide-based targeting reagents are desired.Keywords
This publication has 85 references indexed in Scilit:
- Valency and affinity control of aptamer-conjugated nanoparticles for selective cancer cell targetingJournal of Controlled Release, 2023
- Aptamers with Tunable Affinity Enable Single‐Molecule Tracking and Localization of Membrane Receptors on Living Cancer CellsAngewandte Chemie International Edition, 2020
- Analysis of Modified Nucleotide Aptamer Library Generated by Thermophilic DNA PolymerasesChemBioChem, 2020
- Tracing Oncogene Rearrangements in the Mutational History of Lung AdenocarcinomaCell, 2019
- Pharmacokinetics, pharmacodynamics and safety of aptamersAdvanced Drug Delivery Reviews, 2018
- Emerging functions of the EGFR in cancerMolecular Oncology, 2017
- Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectivesInternational Journal of Cancer, 2015
- Aptamer‐Based Affinity Labeling of ProteinsAngewandte Chemie International Edition, 2012
- Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degenerationGraefe's Archive for Clinical and Experimental Ophthalmology, 2009
- Regulatory aspects of drug approval for macular degenerationAdvanced Drug Delivery Reviews, 2005